Personalised medicine: what is it, and what does it mean for patients and the NHS?
EDITED: 14/04/2016 |
Over 100 parliamentarians and stakeholders crowded into the Attlee Suite of Portcullis House on Wednesday 15 March to celebrate the official launch of the All-Party Group on Personalised Medicine.
UK Life Sciences Minister George Freeman MP set the event off by highlighting the importance of data integration and the vital role of patient voice in realising the full potential of personalised medicine in the NHS. Professor Peter Johnson and Professor Hugh Watkins then explained what personalised medicine means for cancer and cardiac patients respectively.
A cream tea reception followed where attendees had the opportunity to explore four stalls showcasing varied examples of innovative products designed to deliver better, more tailored patient care in the future.
Quotes from the day
“I really welcome this All-Party Group…its coming to be formed at a time when this subject will need real high quality debate in both Houses”
Personalised medicine “really relies on the oil of data and getting that oil to flow through the system”.
George Freeman MP
Parliamentary Under Secretary of State for Life Sciences
“As a two time cancer survivor, personalised medicine has been a dream of mine and I am keen to move this APPG forward…I believe this group will provide a much-needed forum, for productive discussion and insightful debate, on how personalised medicine offers us opportunities to provide a more efficient and effective NHS.”
Jo Churchill MP
Chair APPG on Personalised Medicine
“If I had one wish for this Group, of which I am a huge supporter and which I believe has huge potential, it’s to encourage our colleagues at NHSE to develop, very rapidly, a strategy for the implementation of personalised cancer medicine…and personalised medicine more broadly, and to bring it forward in England.”
Prof Peter Johnson MA MD FRCP
Chief Clinician, Cancer Research UK
Professor of Medical Oncology, University of Southampton